FDA forges ties with WebMD for drug safety

15 December 2008

The US Food and Drug Administration has announced a first-of-its-kind accord with the leading on-line specialist health care web site, WebMD.com. The move is "only the first of what the FDA and WebMD expect to be an evolving partnership."

The federal agency's Commissioner, Andrew von Eschenbach, pointed to its new partner's 50 million unique visitors per month and WebMD the Magazine's nine million print readers to explain the decision. He said: "this is going to enable the FDA bringing to millions of people timely product-safety alerts and important health information."

Among the initial phase of collaborations between the FDA and WebMD are: a facility for members of the public to report problems with drugs and other agency-monitored products; health alerts from the government; links to relevant parts of the FDA's own web site; and the gathering of feedback from the public, including on-line opinion polls for the FDA's benefit.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight